Dataset from An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Formulation of IXAZOMIB (MLN9708), Administered Twice-weekly in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment

The purpose of this study is to determine the safety, tolerability, maximum tolerated dose
(MTD), and recommended phase 2 dose (RP2D) in phase 1 and to determine the combined response
rate of clinical response CR and very good partial response (VGPR) in phase 2 of oral (PO)
ixazomib administered twice-weekly in combination with lenalidomide and low-dose
dexamethasone in a 21-day cycle in participants with newly diagnosed multiple myeloma (NDDM).